The trial, sponsored by Peking University, aims to evaluate the safety of PD-1 knockout engineered T cells in patients with castration-resistant prostate cancer (CRPC) who have progressed after standard treatments. Given the increasing interest in immunotherapies and the potential for PD-1 inhibitors in oncology, this asset could represent a significant advancement in CRPC treatment. However, the trial has been withdrawn due to lack of funding, which raises concerns about the financial viability and support for further development. The CRPC market is competitive, with established therapies and emerging immunotherapies, necessitating a strong funding strategy and potential partnerships for successful commercialization.